Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
Cremolini, C; Antoniotti, C; Rossini, D; Lonardi, S; Loupakis, F; Pietrantonio, F; Bordonaro, R; Latiano, TP; Tamburini, E; Santini, D; Passardi, A; Marmorino, F; Grande, R; Aprile, G; Zaniboni, A; Murgioni, S; Granetto, C; Buonadonna, A; Moretto, R; Corallo, S; Cordio, S; Antonuzzo, L; Tomasello, G; Masi, G; Ronzoni, M; Di Donato, S; Carlomagno, C; Clavarezza, M; Ritorto, G; Mambrini, A; Roselli, M; Cupini, S; Mammoliti, S; Fenocchio, E; Corgna, E; Zagonel, V; Fontanini, G; Ugolini, C; Boni, L; Falcone, A
Falcone, A (corresponding author), Azienda Osped Univ Pisana, Unit Med Oncol 2, I-56126 Pisa 67, Italy.
LANCET ONCOLOGY, 2020; 21 (4): 497
